UPGRADING CORE FACILITY FOR DNA SEQUENCING AND MAPPING

建议通过增加ABI PRISM 377 DNA测序仪，升级测序硬件和GENESCAN， GENOTYPER和序列升级软件，对现有DNA核心设施进行升级。该仪器将在兽医学院最近翻新的核心设施中安装和操作，并由来自兽医学院和医学院11个不同部门的主要用户组成的委员会监督，这些部门都位于校园的一到两个街区内。主要用户包括31个研究小组（超过170名研究人员），拥有超过88项联邦和非联邦拨款，他们将在大约85%的时间内使用该设备。主要用户群的研究兴趣集中在细胞和分子生物学的基础和临床方面，包括转基因，集中在细胞和分子生物学的基础和临床方面，包括转基因。组蛋白、血红蛋白和免疫球蛋白基因表达的发育方面，胚胎发生、肌肉发生、线粒体和核基因相互作用中的基因表达，肝和脑药物代谢中的两性二态性，致畸，细胞转化，缺氧/灌注，离子通道的结构和功能，神经细胞的信号转导，艾滋病和相关的神经肌肉和血液疾病，遗传性代谢性疾病的遗传障碍特征及各种动物模型中基因治疗的进展。31个主要用户均对高效DNA测序有需求。其中约有12组对突变分析和基因定位技术有直接需求，另外6组在未来2-3年内需要这些设施。该设施将由一位经验丰富的生物化学家/分子生物学家管理，他在过去的9年里一直管理着核心设施。

It is proposed to upgrade the existing DNA core facility by adding an ABI PRISM 377 DNA sequencer, with an upgraded sequence hardware and GENESCAN, GENOTYPER and sequence upgrade softwares. The instrument will be housed and operated in the recently renovated core facility at the School of Veterinary Medicine, and supervised by a Committee of major users from 11 different departments of the School of Veterinary Medicine and School of Medicine, all located within a one to two block area of the campus. The major users consist of 31 research groups (over 170 research personnel) with over 88 federal and non-federal grants, who will use this equipment for about 85% of the time. The research interests of the major user group are focused on the basic as well as clinical aspects of cell and molecular biology, including transgenesis, are focused on the basic as well as clinical aspects of cell and molecular biology, including transgenesis. developmental aspects of histone, hemoglobin, and immunoglobin gene expression, gene expressing during embryogenesis, myogenesis, mitochondrial and nuclear gene interaction, sexual dimorphism in hepatic and brain drug metabolism, teratogenesis, cell transformation, hypoxia/perfusion, structure and function of ion channels, signal transduction in neural cells, AIDS and related neuromuscular and hematopeitic diseases, characterization of genetic disorders of inherited metabolic diseases and development of gene therapy in various animal models. All of the 31 major users have requirements for high efficiency DNA sequencing. About 12 of them have immediate requirements for mutational analysis and gene mapping techniques, and an additional 6 groups need these facilities within the next 2-3 years. The facility will be run by an experienced biochemist/molecular biologist who has been managing the core facility for the past nine years.